Cefdinir for Bullous Impetigo Treatment

Bullous Impetigo: Causative Organisms and Presentation

Bullous impetigo is caused exclusively by Staphylococcus aureus strains that produce toxins cleaving the dermal-epidermal junction, presenting as fragile, thin-roofed vesicopustules that may rupture, creating crusted, erythematous erosions, and is solely staphylococcal in origin 1, 3
Unlike non-bullous impetigo, bullous impetigo is characterized by its exclusive causation by S. aureus, which differentiates it from non-bullous impetigo that can be caused by both S. aureus and Streptococcus pyogenes 1

For limited lesions, topical antibiotics like mupirocin or retapamulin twice daily for 5 days are first-line therapy, as recommended by the Infectious Diseases Society of America 2, 3
Topical therapy is as effective as oral antibiotics for limited impetigo, with clinical cure rates comparable to oral therapy 1

Oral therapy is recommended for patients with numerous lesions or in outbreaks affecting several people, and should be active against S. aureus, with dicloxacillin or cephalexin as first-line options 2, 3
When MRSA is suspected or confirmed, doxycycline, clindamycin, or sulfamethoxazole-trimethoprim (SMX-TMP) are recommended, highlighting the importance of considering local resistance patterns 2, 3

As an extended-spectrum semisynthetic cephalosporin, cefdinir has activity against S. aureus comparable to second-generation agents, making it a potential option for treating bullous impetigo 4, 5

For limited lesions, use topical mupirocin or retapamulin twice daily for 5 days, while for extensive lesions requiring oral therapy, first-line options include dicloxacillin or cephalexin for 7 days, with cefdinir as an alternative when first-line options are not suitable 1, 2, 3
When MRSA is suspected, doxycycline, clindamycin, or SMX-TMP are recommended, emphasizing the need for empiric therapy to cover MRSA until culture results are available 2, 3

Penicillin alone is not effective for bullous impetigo since it's caused by S. aureus, and cefdinir is ineffective against methicillin-resistant S. aureus (MRSA) 6
In areas with high MRSA prevalence, empiric therapy should cover MRSA until culture results are available, and systemic antimicrobials should be used during outbreaks of poststreptococcal glomerulonephritis to eliminate nephritogenic strains 1, 2